Barasertib

small molecule

Identifier: CI-DRUG-00000100
Entity page: /drug/barasertib ↗
Edges: 22

Neighbours: 6 cancers1 genes12 trials
Drawn: 19 of 19 neighbours (cap 60); table lists every fetched edge

Accepted: cancer:<slug>, gene:<symbol>, variant:<slug>, drug:<slug>, trial:<NCT id>, or a bare CI id. Find slugs with search.

Most connectedLung Non-Small Cell Carcinoma 3,147 Malignant Colorectal Neoplasm 1,866 ABL1 298 EGFR 276 Imatinib 450 Dasatinib 321

Neighbourhood

Radial view

Focus at the centre; neighbours grouped by entity type. Click a node to re-centre the graph on it; ↗ opens the entity page. Hover a spoke for relationship, evidence level, cancer context and source.

Edges

Every edge, grouped by relationship

Source-native edges first (aggregated per neighbour, direction, evidence level and source), then derived registry links. Up to 15 per relationship (10 trials); “show all” raises one group to 200.

Relationship	Neighbour	Direction	Evidence level	Cancer context	Support	Claim	Source	Expand
Barasertib targets …TARGETS1 of 1
→ targets	AURKB	—	INHIBITOR	—	1	Curated	chembl	graph →
Barasertib investigated for …INVESTIGATED_FOR4 of 4
→ investigated for	Acute Myeloid Leukemiahematologic_malignancy	unknown	2

Barasertib investigated in trials for …INVESTIGATED_IN_TRIALSderived5 of 5
→ investigated in trials for	Acute Myeloid Leukemiahematologic_malignancy 5 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Acute Myeloid Leukemia	5	Observed	clinicaltrials	graph →
→ investigated in trials for	Solid Neoplasm 3 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	3	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Small Cell Carcinoma 2 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Small Cell Carcinoma	2	Observed	clinicaltrials	graph →
→ investigated in trials for	Lymphomacancer_family 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lymphoma	1	Observed	clinicaltrials	graph →
→ investigated in trials for	Myeloid Leukemiahematologic_malignancy 1 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Myeloid Leukemia	1	Observed	clinicaltrials	graph →

Barasertib investigated in trials for …INVESTIGATED_IN_TRIALSderived5 of 5

→ investigated in trials for

Acute Myeloid Leukemiahematologic_malignancy

5 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Acute Myeloid Leukemia

Observed

Barasertib studied in …STUDIED_INderived12 of 12show fewer
→ studied in	NCT04745689Phase 2 · active not recruiting Study of AZD2811 + Durvalumab in ES-SCLC · 12 trials list this drug (1 active)	—	—	Lung Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT03217838Phase 1 · terminated Safety, Tolerability, Pharmacokinetics, and Efficacy of AZD2811 Nanoparticles as Monotherapy or in Combination in Acute Myeloid Leukemia Participants. · 12 trials list this drug (1 active)	—	—	Acute Myeloid Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT02579226Phase 1 · completed A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors. · 12 trials list this drug (1 active)	—	—	Solid Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT00952588Phase 2/Phase 3 · completed Study to Investigate the Efficacy, Safety and Tolerability of AZD1152 Alone and in Combination With Low Dose Cytosine Arabinoside (LDAC)in Acute Myeloid Leukaemia (AML) Patients · 12 trials list this drug (1 active)	—	—	Acute Myeloid Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT03366675Phase 2 · terminated AZD 2811 Monotherapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N3] · 12 trials list this drug (1 active)	—	—	Lung Small Cell Carcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT01354392Phase 1/Phase 2 · completed AZD1152 in Diffuse Large B-cell Lymphoma · 12 trials list this drug (1 active)	—	—	Lymphoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT00926731Phase 1 · completed Study to Assess the Safety and Tolerability of AZD1152 in Combination With Low Dose Cytosine Arabinoside (LDAC) · 12 trials list this drug (1 active)	—	—	Acute Myeloid Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT00497991Phase 1 · completed Safety, Tolerability, PK and Efficacy of AZD1152 in Patients With Relapsed Acute Myeloid Leukemia · 12 trials list this drug (1 active)	—	—	Myeloid Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT01019161Phase 1 · completed An Open Label, Single Centre Mass Balance C14 Study in Patients With Acute Myeloid Leukaemia (AML) · 12 trials list this drug (1 active)	—	—	Acute Myeloid Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT00530699Phase 1 · completed Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML) · 12 trials list this drug (1 active)	—	—	Acute Myeloid Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT00497731Phase 1 · terminated AZD1152 in Patients With Advanced Solid Malignancies-Study 1 · 12 trials list this drug (1 active)	—	—	Solid Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT00497679Phase 1 · terminated AZD1152 in Patients With Advanced Solid Malignancies-Study 3 · 12 trials list this drug (1 active)	—	—	Solid Neoplasm	1	Observed	clinicaltrials	graph →

Radial view

Every edge, grouped by relationship

Paths